Fulminant fatal swine influenza (H1N1): Myocarditis, myocardial infarction, or severe influenza pneumonia?
The swine influenza (H1N1) pandemic began in Mexico and rapidly spread worldwide. As is the case with pandemic influenza A, the majority of early deaths have been in young healthy adults. The complications of pandemic H1N1 have been reported from several centers. Noteworthy has been the relative rarity of bacterial coinfection in bacterial pneumonia in hospitalized adults with H1N1 pneumonia. Simultaneous bacterial community-acquired pneumonia due to methicillin-sensitive Staphylococcus aureus or community-acquired methicillin resistant S. aureus and subsequent bacterial community-acquired pneumonia due to S. pneumoniae or Haemophilus influenzae have been reportedly rare (0.4%-4% of well-documented cases). Cardiac complications of H1N1 infection have been uncommon. Young healthy adults without a cardiac history who have H1N1 and chest pain usually have either acute myocardial infarction or acute myocarditis. Cardiac symptomatology with H1N1 often overshadows pulmonary manifestations, that is, influenza pneumonia. With H1N1 pneumonia, clinicians should be alert for otherwise unexplained tachycardia or chest pain that may represent acute myocardial infarction or myocarditis. We present a case of rapidly fatal H1N1 in a young adult treated with oseltamivir and peramivir. He was initially tachycardic, thought to represent myocarditis. He subsequently became hypotensive and expired. At autopsy there was cardiomegaly present but there were no signs of acute myocardial infarction or myocarditis. Pathologically, he died of severe H1N1 pneumonia and not bacterial pneumonia.
Cunha
Burke A
BA
Infectious Disease Division, Winthrop-University Hospital, Mineola, New York 11501, USA.
Syed
Uzma
U
Mickail
Nardeen
N
D000081:Acetamides / Q000627:therapeutic use; D000146:Acids, Carbocyclic; D000328:Adult; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D003517:Cyclopentanes / Q000627:therapeutic use; D017809:Fatal Outcome; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000302:isolation & purification*; D007251:Influenza, Human / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D000069349:Linezolid; D008297:Male; D000077731:Meropenem; D009203:Myocardial Infarction / Q000175:diagnosis / Q000209:etiology*; D009205:Myocarditis / Q000175:diagnosis / Q000209:etiology*; D023303:Oxazolidinones / Q000627:therapeutic use; D011024:Pneumonia, Viral / Q000175:diagnosis / Q000209:etiology*; D013845:Thienamycins / Q000627:therapeutic use
D000081:Acetamides; D000146:Acids, Carbocyclic; D000900:Anti-Bacterial Agents; D003517:Cyclopentanes; D006146:Guanidines; D023303:Oxazolidinones; D013845:Thienamycins; D000077731:Meropenem; D000069349:Linezolid; C414210:peramivir